| Drug Name |
Nitazoxanide |
| Drug ID |
BADD_D01571 |
| Description |
Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths [A31976]. Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses [A31977]. |
| Indications and Usage |
For the treatment of diarrhea in adults and children caused by the protozoa Giardia lamblia, and for the treatment of diarrhea in children caused by the protozoan, Cryptosporidium parvum [FDA label].
Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976]. |
| Marketing Status |
approved; investigational; vet_approved |
| ATC Code |
P01AX11 |
| DrugBank ID |
DB00507
|
| KEGG ID |
D02486
|
| MeSH ID |
C041747
|
| PubChem ID |
41684
|
| TTD Drug ID |
D08EBN
|
| NDC Product Code |
11014-0127; 43386-405; 64980-526; 11014-0128; 69766-077; 11014-0178; 11014-0384; 69575-4038; 67546-111; 67546-212; 68022-7020; 70966-0013; 57741-3800; 51927-5207; 71052-232 |
| UNII |
SOA12P041N
|
| Synonyms |
nitazoxanide | 2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide | Taenitaz | Colufase | Daxon | Heliton | NTZ | Alinia | Cryptaz |
